Login to Your Account

Vertex, GSK In Potential $405M VX-409 Preclinical Collaboration

By Karen Pihl-Carey

Wednesday, December 14, 2005
Partnering a promising preclinical pain product, Vertex Pharmaceuticals Inc. granted GlaxoSmithKline plc worldwide development and commercialization rights in a deal worth up to $405 million plus royalties. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription